ArticlePsychopharmacology2005
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.
Article in Psychopharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.Translational psychiatry · 2018Trial
- AMPA receptors modulate enhanced dopamine neuronal activity induced by the combined administration of venlafaxine and brexpiprazole.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Integrative multi-omics landscape of fluoxetine action across 27 brain regions reveals global increase in energy metabolism and region-specific chromatin remodelling.Molecular psychiatry · 2022Article
- 5-HT Receptors and the Development of New Antidepressants.International journal of molecular sciences · 2021Review
- In vivo electrophysiological recordings of the effects of antidepressant drugs.Experimental brain research · 2019Review
- A heuristic model for working memory deficit in schizophrenia.Biochimica et biophysica acta · 2016Article
- Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study.The international journal of neuropsychopharmacology · 2015Article
- Serotonin and beyond: therapeutics for major depression.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013Review
- Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.The Journal of pharmacology and experimental therapeutics · 2011Article
- Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.CNS neuroscience & therapeutics · 2010Review
- Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2009Review
- Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.The international journal of neuropsychopharmacology · 2009Article
- Epigenetic principles and mechanisms underlying nervous system functions in health and disease.Progress in neurobiology · 2008Review
- Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.Drugs · 2008Review
- In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus.Naunyn-Schmiedeberg's archives of pharmacology · 2008Article
- Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons.Psychopharmacology · 2007Article
- Lurasidone: a new treatment option for bipolar depression-a review.Innovations in clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe depressive phase of bipolar disorder (bipolar depression) is a difficult-to-treat form of depression. The olanzapine/fluoxetine combination (Symbyax) is the only medication approved to treat this disorder. The precise neural mechanisms responsible for its efficacy are not clearly understood.
objectivesIn order to further elucidate the neurobiological mechanisms responsible for the beneficial clinical effects of the olanzapine/fluoxetine combination, the current experiment was designed to investigate the effects of chronic coadministration of olanzapine and fluoxetine on electrophysiological activity in the locus coeruleus (LC).
methodsRats received olanzapine for 3 weeks via subcutaneous osmotic pumps while simultaneously receiving daily intraperitoneal injections of fluoxetine. These chronically treated rats were anesthetized, and single-unit recordings of LC neurons were made.
resultsChronic administration of olanzapine alone significantly increased firing of LC neurons, while, as reported previously, chronic administration of fluoxetine alone significantly reduced firing of LC neurons. However, in the combination condition, olanzapine was able to block the fluoxetine-induced suppression of the LC, and a significant increase in LC activity was observed.
conclusionsThe observed increase in firing of LC neurons could lead to enhanced levels of norepinephrine release in projection areas and amelioration of the clinical symptoms of bipolar depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.